64 related articles for article (PubMed ID: 19177002)
1. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
Guillard S; Clarke PA; Te Poele R; Mohri Z; Bjerke L; Valenti M; Raynaud F; Eccles SA; Workman P
Cell Cycle; 2009 Feb; 8(3):443-53. PubMed ID: 19177002
[TBL] [Abstract][Full Text] [Related]
2. Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Workman P; Clarke PA; Raynaud FI; van Montfort RL
Cancer Res; 2010 Mar; 70(6):2146-57. PubMed ID: 20179189
[TBL] [Abstract][Full Text] [Related]
3. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.
Bax DA; Little SE; Gaspar N; Perryman L; Marshall L; Viana-Pereira M; Jones TA; Williams RD; Grigoriadis A; Vassal G; Workman P; Sheer D; Reis RM; Pearson AD; Hargrave D; Jones C
PLoS One; 2009; 4(4):e5209. PubMed ID: 19365568
[TBL] [Abstract][Full Text] [Related]
4. Structural model of active Bax at the membrane.
Bleicken S; Jeschke G; Stegmueller C; Salvador-Gallego R; García-Sáez AJ; Bordignon E
Mol Cell; 2014 Nov; 56(4):496-505. PubMed ID: 25458844
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule Bax agonists for cancer therapy.
Xin M; Li R; Xie M; Park D; Owonikoko TK; Sica GL; Corsino PE; Zhou J; Ding C; White MA; Magis AT; Ramalingam SS; Curran WJ; Khuri FR; Deng X
Nat Commun; 2014 Sep; 5():4935. PubMed ID: 25230299
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.
Miyashita T; Reed JC
Cell; 1995 Jan; 80(2):293-9. PubMed ID: 7834749
[TBL] [Abstract][Full Text] [Related]
7. Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
Zając A; Sumorek-Wiadro J; Langner E; Wertel I; Maciejczyk A; Pawlikowska-Pawlęga B; Pawelec J; Wasiak M; Hułas-Stasiak M; Bądziul D; Rzeski W; Reichert M; Jakubowicz-Gil J
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068110
[TBL] [Abstract][Full Text] [Related]
8. Predicting mechanism of action of cellular perturbations with pathway activity signatures.
Ren Y; Sivaganesan S; Clark NA; Zhang L; Biesiada J; Niu W; Plas DR; Medvedovic M
Bioinformatics; 2020 Sep; 36(18):4781-4788. PubMed ID: 32653926
[TBL] [Abstract][Full Text] [Related]
9. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
Clarke PA; Roe T; Swabey K; Hobbs SM; McAndrew C; Tomlin K; Westwood I; Burke R; van Montfort R; Workman P
Oncogene; 2019 Jun; 38(25):5076-5090. PubMed ID: 30905967
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles.
Rychahou P; Bae Y; Reichel D; Zaytseva YY; Lee EY; Napier D; Weiss HL; Roller N; Frohman H; Le AT; Mark Evers B
J Control Release; 2018 Apr; 275():85-91. PubMed ID: 29421609
[TBL] [Abstract][Full Text] [Related]
11. Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives.
Ong PS; Wang LZ; Dai X; Tseng SH; Loo SJ; Sethi G
Front Pharmacol; 2016; 7():395. PubMed ID: 27826244
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
[TBL] [Abstract][Full Text] [Related]
13. Drugging PI3K in cancer: refining targets and therapeutic strategies.
Yap TA; Bjerke L; Clarke PA; Workman P
Curr Opin Pharmacol; 2015 Aug; 23():98-107. PubMed ID: 26117819
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.
Cage TA; Chanthery Y; Chesler L; Grimmer M; Knight Z; Shokat K; Weiss WA; Gustafson WC
Front Oncol; 2015; 5():111. PubMed ID: 26029667
[TBL] [Abstract][Full Text] [Related]
15. A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes.
Hill R; Kalathur RK; Callejas S; Colaço L; Brandão R; Serelde B; Cebriá A; Blanco-Aparicio C; Pastor J; Futschik M; Dopazo A; Link W
Breast Cancer Res; 2014 Dec; 16(6):482. PubMed ID: 25488803
[TBL] [Abstract][Full Text] [Related]
16. Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
Al-Saffar NM; Marshall LV; Jackson LE; Balarajah G; Eykyn TR; Agliano A; Clarke PA; Jones C; Workman P; Pearson AD; Leach MO
PLoS One; 2014; 9(8):e103835. PubMed ID: 25084455
[TBL] [Abstract][Full Text] [Related]
17. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.
Potter DS; Kelly P; Denneny O; Juvin V; Stephens LR; Dive C; Morrow CJ
Neoplasia; 2014 Feb; 16(2):147-57. PubMed ID: 24709422
[TBL] [Abstract][Full Text] [Related]
18. mTOR pathway in colorectal cancer: an update.
Francipane MG; Lagasse E
Oncotarget; 2014 Jan; 5(1):49-66. PubMed ID: 24393708
[TBL] [Abstract][Full Text] [Related]
19. Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.
Kim MS; Kim JE; Lim DY; Huang Z; Chen H; Langfald A; Lubet RA; Grubbs CJ; Dong Z; Bode AM
Cancer Prev Res (Phila); 2014 Feb; 7(2):236-45. PubMed ID: 24327721
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells.
Carminati PO; Donaires FS; Marques MM; Donadi EA; Passos GA; Sakamoto-Hojo ET
Mol Biol Rep; 2014 Jan; 41(1):165-77. PubMed ID: 24218165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
